Elucidate Bio’s AI platform selects the right patients for every cancer drug.

Pharma is forced to play a guessing game about which patients to enroll in oncology clinical trials, causing a 95% failure rate and costing $60B. This happens because of slow tumor analysis with minimal biological depth: current methods measure ~550 datapoints/tumor over 3 months with 80% accuracy.

Elucidate Bio evaluates 4 Trillion datapoints/tumor in 3 days with 95% accuracy, revealing why patients respond to therapy, and which to select for clinical trials.

By selecting the right patients and doubling the objective response rate, this can triple market share for pharma.